ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,309 GBX | -0.49% |
|
+1.47% | +16.00% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
154.8
USD
Average target price
166.8
USD
Spread / Average Target
+7.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.00% | 240B | |
| +29.20% | 684B | |
| +29.59% | 568B | |
| -3.94% | 361B | |
| +18.43% | 329B | |
| +4.51% | 284B | |
| +9.36% | 208B | |
| -7.03% | 200B | |
| +7.58% | 166B | |
| -1.25% | 159B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Trial
